Evaluating urine tests for detecting bladder cancer
Official title: Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney
Run by Lahey Clinic · NCT00872495 · Data updated 2026-11-12
This study is testing if urine tests that look for DNA and proteins can help detect bladder and kidney cancers in patients undergoing treatment or with a history of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Lahey Clinic Academic / other |
| Locations | 1 site (Burlington, Massachusetts) |
| Status | Recruiting |
| Started | September 2002 |
| Main results expected | October 2028 |
| Study ends | November 2028 |
| Registry record updated | December 8, 2025 |
| Trial ID | NCT00872495 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients over 18 years old who are scheduled for procedures related to bladder cancer or have recurrent disease.
✕Probably not a fit
Patients under 18 years of age or those without any evidence of bladder cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the effectiveness of analyzing DNA and protein material found in urine for the detection of urothelial cancer, specifically bladder and kidney cancers. By examining these non-invasive assays, the study seeks to understand how they can aid in predicting cancer behavior, including remission and recurrence rates. The research focuses on patients undergoing procedures related to bladder cancer, including nephroureterectomy and cystectomy, as well as those with recurrent disease. A control group will also be included to compare results with individuals who have no known bladder cancer.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and non-invasive methods for early detection and monitoring of bladder cancer.
How similar studies have gone: Previous studies have explored non-invasive assays for bladder cancer detection, indicating potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled to have a nephroureterectomy, cystectomy, cytoscopy (newly diagnosed bladder cancer and those with recurrent disease in follow up) * Control Group: No known evidence of bladder cancer-one urine sample * \> than 18 years of age Exclusion Criteria: * \< than 18 years of age
Where it's running
-
Lahey Clinic, Inc.
Burlington, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Kimberly Rieger-Christ, PhD — Lahey Clinic, Inc.
- Study coordinator: Kimberly Rieger-Christ, PhD
- Email: Kimberly.R.Christ@lahey.org
- Phone: 781-744-2969
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sequential gemcitabine plus Jelmyto for favorable high-grade upper tract urothelial cancer
This trial tests whether giving gemcitabine followed by Jelmyto directly into the kidney can control favorable high‑grade upper tract urothelial cancer and help people avoid kidney removal.
-
Using Pembrolizumab after Tri-modality Treatment for Muscle-invasive Bladder Cancer
This study is testing if the drug pembrolizumab can help people with muscle-invasive bladder cancer stay cancer-free after they’ve had surgery and other treatments.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer
This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.
-
BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy
This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.